Articles

A doctor finishes a consultation and turns back to their screen. An AI tool summarises the latest literature, compares treatment options and highlights the most relevant guideline recommendations. The doctor reviews the summary, considers the patient context and makes a decision.
A doctor finishes a consultation and turns back to their screen. An AI tool summarises the latest literature, compares treatment options and highlights the most relevant guideline recommendations. The doctor reviews the summary, considers the patient context and makes a decision. Later that day a pharmaceutical representative arrives to discuss the same therapy, inevitably, his words or slides compete with excerpts and recommendations from multiple AI sources the doctor has already reviewed. Situations like this ar…

Oxygen-based therapies are attracting renewed interest from pharma and biotech companies, driven by rising respiratory disease burden, aging populations and advances in portable medical technologies. Investment is moving outside traditional respiratory support into areas such as portable oxygen concentrators, digital monitoring systems and HBOT, which is being studied for neurological and regenerative therapies.
Oxygen-based therapies have long been part of standard medical care, but they’re now drawing fresh interest from investors and innovators alike. As healthcare systems adapt to rising chronic disease rates and the growing demand for home-based treatment, oxygen-based therapies are moving into a more commercial space. Pharma companies, biotech firms and medical device manufacturers ar…

Real-world evidence is increasingly demonstrating tobacco harm reduction (THR) in action, so why do many public health bodies and regulators remain sceptical? Joe Thompson, Group Science & Regulatory Affairs Director at Imperial Brands, builds on his panel contribution at the World Nicotine Congress to examine the arguments.
Real-world evidence is increasingly demonstrating tobacco harm reduction (THR) in action, so why do many public health bodies and regulators remain sceptical? Joe Thompson, Group Science & Regulatory Affairs Director at Imperial Brands, builds on his panel contribution at the World Nicotine Congress to examine the arguments. Increasingly, it’s real-world data – not just laboratory and clinical testing – that’s complementing the existing evidence base and helping fil…

To operate successfully in a Good Manufacturing Practice (GMP) regulated contract testing environment, an organisation needs more than documented procedures and validated systems. Sustained compliance depends on the culture that surrounds those systems and shapes how people apply them every day. Here, Emmet Tilley, Quality Director at scientific and regulatory consultancy Broughton Group, outlines how creating a quality culture through established practices with new perspectives enables growth while maintaining regulatory integrity.
To operate successfully in a Good Manufacturing Practice (GMP) regulated contract testing environment, an organisation needs more than documented procedures and validated systems. Sustained compliance depends on the culture that surrounds those systems and shape…

Unprecedented demand for specialized talent has increased scrutiny regarding professional credentialing...
Summary: Unprecedented demand for specialized talent has increased scrutiny regarding professional credentialing. Traditional verification methods have become inadequate as health care has expanded across borders. This paradigm shift has merged centralized governance with the capabilities of blockchain technology. Now, professionals have more powerful solutions to mitigate credentialing fraud and accelerate talent. The High Stakes of Credentialing in Life Sciences Life sciences and pharmaceutical professionals must understand the consequences of credentialing. Patient safety and human health are among the top concerns for both clinical researchers and lab technicians. Modern medicine i…

Predictive workforce analytics is transforming how Managed Service Providers (MSPs) support staffing in integrated care systems...
Summary Predictive workforce analytics is transforming how Managed Service Providers (MSPs) support staffing in integrated care systems. By analyzing historical workforce data, patient demand patterns and operational trends, predictive tools allow MSPs to anticipate staffing needs rather than react to shortages. This approach helps health care organizations align the right mix of clinicians and support staff with fluctuating demand, improving efficiency, reducing labor costs and maintaining high-quality care delivery. Predictive analytics also supports long-term workforce planning by identifying potential skill gaps, turnover risks and demand surges. As integrat…

ArcaScience, founded by brain cancer survivor Romain Clement, uses AI to transform benefit–risk analysis in drug development. With 100B+ biomedical data points, it helps pharma giants like Sanofi & AstraZeneca speed safer therapies to patients. Fresh off a $7M raise, ArcaScience is expanding in the US, launching patient-facing tools, and setting a new global standard for drug evaluation.
Q1: In a recent keynote at Health.tech, you spoke about your own journey as a patient for the first time. Can you tell us more about this defining moment, and how this led to ArcaScience?  I was 19 when a radiologist pointed at a 9-centimeter mass on my MRI scan.  Being with my mom at that moment, I cared more about what she felt rather than what I was supposed to assess. The diagnosis was presented to me a…

The Hospital Capacity Management Solutions Market is experiencing rapid growth due to increasing pressure on healthcare systems to optimize resources and improve patient flow. Valued at over USD 5.3 billion in 2025, the market is projected to reach USD 24.4 billion by 2035, growing at a strong CAGR of 18.5%. These solutions help hospitals efficiently manage beds, staff, equipment, and patient movement in real time, improving operational efficiency and care quality. Growth is driven by rising chronic diseases, advancements in healthcare IT (like AI and predictive analytics), and the need for cost-effective operations. However, challenges such as integration with legacy systems and resistance to workflow changes may hinder adoption.
The global hospital capacity management solutions market…

Amid an increasingly difficult energy landscape, Steve Ennis, Manufacturing Sector Manager for Aggreko, discusses the potential for battery storage to address grid shortages, spiking energy costs, and sustainability pressures through a number of key applications.
It is hard to imagine a more challenging energy landscape for European pharmaceutical manufacturers at present. Even before recent geopolitical developments caused energy prices to spike, industrial energy costs were, on average, over double that of the United States, and nearly 50% above those in China.[1] Regardless of how the market may shift, the ‘energy trilemma’ that European pharmaceutical manufacturers need to manage to stay competitive remains the same: Resilience – The ability to keep production flowing, even in the face…

Pharmaceutical innovation exists to improve patient outcomes. Yet between laboratory discovery and patient benefit lies a critical intermediary: conversation. The way clinical evidence is explained, challenged and contextualised in discussions with healthcare professionals (HCPs) plays a meaningful role in how new therapies are understood and adopted in practice. At the same time, the profile of those leading these conversations is changing.
A Broader Talent Model Pharmaceutical commercial models across Europe have shifted towards hybrid engagement structures and greater use of Contract Sales Organisations (CSOs), increasing flexibility in how field teams are deployed.¹ ² Recruitment patterns have diversified in parallel. In the UK, representatives are not required to hold medical, pharma…

Gene and cell therapy is moving fast – and in a clear direction. Programs are pushing toward more complex payloads, virus-free engineering, and manufacturing models that can scale from early research to late-stage clinical supply without exploding timelines or cost of goods. At the same time, the field is confronting familiar constraints: viral-vector bottlenecks, payload limits, and the risk that DNA elements that are useful for bacterial cloning can become unwanted baggage when the DNA is used as starting material for therapeutics...
Gene and cell therapy is moving fast – and in a clear direction. Programs are pushing toward more complex payloads, virus-free engineering, and manufacturing models that can scale from early research to late-stage clinical supply without exploding timelines o…

Workplace attrition threatens operational continuity and clinical trial timelines for life science professionals. The recent shift to remote and decentralized trials presents unique challenges. Fuelled by systemic issues like burnout and depersonalization, and the unique pressures of data-intensive remote work, traditional retention strategies are failing. AI-augmented managed service providers (MSPs) offer a predictive alternative that transforms retention into proactive strategies. Modern health care professionals use deep learning to find hidden patterns and analyze workloads. By scheduling against real-world volatility, they can identify attrition risk and incorporate targeted interventions. Ultimately, they create a more resilient workforce. Organizations must vet, implement and measure the ROI of these strategic partnerships. ...

The global digital stethoscopes market is expected to grow at a compound annual growth rate (CAGR) of approximately 6% during the forecast period, reflecting the ongoing transformation of healthcare delivery systems and the increasing demand for advanced diagnostic technologies.
Market Outlook and Growth Trajectory The global digital stethoscopes market is expected to grow at a compound annual growth rate (CAGR) of approximately 6% during the forecast period, reflecting the ongoing transformation of healthcare delivery systems and the increasing demand for advanced diagnostic technologies. As healthcare providers shift toward data-driven and remote care models, digital stethoscopes are gaining prominence as essential tools for accurate and efficient patient assessment. Get Free Sample Repor…

Safety data overload in pharmacovigilance occurs when drug-safety teams receive extremely large volumes of safety information—such as ICSRs, literature reports, EHR data, and social-media inputs—making it difficult to quickly identify genuine safety signals. Excessive and often low-quality data, including duplicates and inconsistencies, can create noise, increase analyst workload, and delay critical risk-management decisions. This challenge affects signal detection and assessment by causing false positives, alert fatigue, and slower regulatory responses. To address it, organizations are increasingly adopting AI-driven analytics, data standardization, automated deduplication, and advanced signal-detection tools to prioritize meaningful safety insights and ensure efficient pharmacovigilance operations.

Digital Pharmaceutical Supply Chain Management Market Set to Grow at 9% CAGR Amid Rising Demand for Transparency and Drug Traceability
Market Overview The digital pharmaceutical supply chain management market is projected to expand at a compound annual growth rate (CAGR) of approximately 9% between 2025 and 2030, reflecting the growing transition toward technology-driven supply chain ecosystems in the pharmaceutical industry. As pharmaceutical supply networks become more complex and globalized, organizations are increasingly adopting digital technologies to improve visibility, efficiency, and operational resilience. Pharmaceutical companies face mounting pressure to maintain product integrity, ensure regulatory compliance, and quickly respond to fluctuating market demands. Digital supply ch…

Post-Marketing Surveillance (PMS), also known as Phase IV monitoring, plays a critical role in evaluating a drug’s safety, effectiveness, and real-world performance after regulatory approval. While pre-approval clinical trials involve limited and controlled patient populations, PMS monitors medicines in broader and more diverse real-world settings, helping detect rare adverse reactions, long-term risks, and drug interactions that may not appear during earlier trials. Through continuous pharmacovigilance activities such as adverse event reporting, observational studies, and patient registries, PMS provides valuable data that guides regulatory actions, including label updates, boxed warnings, risk-management plans, or even market withdrawal when serious safety concerns arise.
What Is Post‑…

Joint Clinical Assessment JCA is a new EU level clinical evaluation process under Regulation 2021 2282. Mandatory from January 2025 for oncology and advanced therapies, it harmonises comparative clinical assessments across member states. Running in parallel with EMA review, JCA reshapes evidence strategy, trial design, and market access planning across pharma and biotech.
The introduction of Joint Clinical Assessment JCA marks one of the most significant regulatory and market access changes in the European pharmaceutical landscape in decades. Established under the European Health Technology Assessment Regulation Regulation 2021 2282, JCA is reshaping how clinical evidence is assessed across EU member states. For professionals working in regulatory affairs, market access, HEOR, clinical dev…

Pharmaceutical sales in the UK are undergoing a gradual but meaningful shift in who represents medicines to healthcare professionals. Increasingly, companies are recruiting sales representatives without traditional medical or scientific backgrounds. This evolution, driven in part by changing commercial models and the growth of Contract Sales Organisations (CSOs) - reflects broader expansion across the UK and European pharmaceutical outsourcing market.
Pharmaceutical sales in the UK are undergoing a gradual but meaningful shift in who represents medicines to healthcare professionals. Increasingly, companies are recruiting sales representatives without traditional medical or scientific backgrounds. This evolution, driven in part by changing commercial models and the growth of Contract Sales O…